Insurtech acquisition unites next-gen AI-powered case design with proven compliance and operational infrastructure NEW YORK, Sept. 29, 2025 /PRNewswire/ --…
The addition of cardiology and neurology experts helps health companies scale evidence-based health products with confidence AUSTIN, Texas, Sept. 25,…
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active…
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,…
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients…
Small-group EDI integration breaks market norms bringing automation and accuracy to ancillary benefits administration for groups of any size. INDIANAPOLIS, Sept.…
VIENNA, Va., Sept. 24, 2025 /PRNewswire/ -- The National Academy of Elder Law Attorneys (NAELA) and the Special Needs Alliance…
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every…
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved…
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis…